Fierce competition to synthesize insulin, David Goeddel
Interviewee: David Goeddel. David Goeddel talks about the other groups working on the insulin problem. (DNAi Location: Manipulation > Production > Players > David Goeddel > The competition)
It was clear that we had, I think two formidable labs as, as competition. One on the west coast, the UCSF group that was taking what we would call the cDNA or natural gene approach, and that was Bill Rutter, Howard Goodman and various colleagues at University of California. And then there was the east coast Harvard group, led by Wally Gilbert. And I mean both very good scientifically, but I think the Gilbert group we held more in, we held them more in awe of, uh-oh, we're going to really have to be, be good if, if Wally's working on this project. But I think that was part of the attraction, and definitely the speed we did it in could only have happened if you had that sort of competition, really allowed us to focus. And from the Harvard side I think, you know, I almost look at them as, Wally as a legend and so you imagine he can do more probably even than that group could. And I think it was on our minds most of the time, you know, probably most days, I mean I thought about it all the time, are we going to hear an announcement that Gilbert has been successful.
howard goodman,gilbert group,gene approach,dnai,interviewee,rutter,insulin,wally,ucsf,awe,east coast,manipulation,west coast,harvard,colleagues,university of california,biotechnology,david goeddel
David Goeddel talks about how another group was trying to make insulin.
David Goeddel was one of the first scientists Herb Boyer hired for the insulin project. Here, David Goeddel talks about Genentech's general strategy for synthesizing insulin.
Walter Gilbert talks about his group's early success with isolating the rat insulin gene and making recombinant rat insulin.
David Goeddel talks about what it was like to work at Genetech during its early days.
In 1980, Genentech became the first publicly traded biotech company. David Goeddel talks about his investment.
David Goeddel talks about the strategy Genentech used in making synthetic insulin.
David Goeddel talks about recombinant DNA.
David Goeddel had a problem: how to synthesize human insulin? His relentless energy and tenacity pushed the insulin project to success. Goeddel relaxes by going mountain-climbing.
The recombinant DNA moratorium meant Gilbert had to go to England's Porton Down facility to try and isolate human insulin. He only had one chance ...
In the late 1970s, there was a moratorium on recombinant DNA work. Gilbert had to go to England's Porton Down facility to try and isolate human insulin.